Roman Fleck is a seasoned venture capital investment professional with extensive experience in operational and company building, as well as a background in pharmaceuticals. They served as Principal Scientist at Boehringer Ingelheim from 1999 to 2006, focusing on drug discovery and development for inflammatory and cardiovascular diseases. Currently, Roman holds several prominent positions, including Board Member at Adularia and Eclosion2 & Cie, Chairman at iktos and Omniose, and Executive Chairman at HDAX Therapeutics. Roman also served as CEO of Janpix Ltd from 2017 to 2022, leading an oncology start-up. They hold an MBA from NYU Stern School of Business and a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology.
This person is not in the org chart
This person is not in any teams
This person is not in any offices